# US 9,435,817 B2 · Detection of synthetic cannabinoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,435,817 B2
- Document ID: US9435817B2
- Status: Granted
- Kind: B2
- Application number: 13/585,630
- Filed: 2012-08-14
- Published: 2013-03-14
- Granted: 2016-09-06
- Earliest claimed: 2011-02-14
- Assignees: Randox Laboratories Limited
- Applicants: Elouard Benchikh; Stephen Peter Fitzgerald; Paul John Innocenzi; Philip Andrew Lowry; Ivan Robert McConnell
- Inventors: Elouard Benchikh; Stephen Peter Fitzgerald; Paul John Innocenzi; Philip Andrew Lowry; Ivan Robert McConnell
- Web page: https://patentgrep.com/patent/US9435817B2

## CPC

- G01N 33/948: {Sedatives, e.g. cannabinoids, barbiturates (opiates G01N33/9486)}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 17/14: Peptides being immobilised on, or in, an inorganic carrier
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.

## Claims

### Claim 1

An antibody that binds to (±)-CP-47,497 (C7 homologue) and (±)-CP-47,497 (C8 homologue),
wherein the antibody has a cross-reactivity presented as B/B0 of ≦50% against (±)-CP-47,497 (C7 homologue) at a concentration of 100 ng/ml, and a cross-reactivity presented as B/B0 of ≦50% against (±)-CP-47,497 (C8 homologue) at a concentration of 100 ng/ml, and
wherein the antibody has a cross-reactivity presented as B/B0 of greater than 80% against each one of the cross-reactants selected from the group consisting of (±)-CP-47,497 (C7 para quinone analogue), (±)-CP-55,940, (−)-CP 55,940, (+)-CP 55, 940, HU-210, HU-211 (dexanabinol), HU-308, delta9-THC, and (−)-11-nor-9-carboxy-delta9-THC, at a cross-reactant concentration of 100 ng/ml,
as determined using (±)-CP-47,497 (C8 homologue) as a standard and Tracer 1,
wherein Tracer 1 has the following structural formula:
wherein HRP is Horse Radish Peroxidase,
wherein B0 is absorbance at 450 nm at zero ng/ml standard concentration, and
wherein B is absorbance at 450 nm at predetermined variable standard concentrations.

### Claim 2

An antibody raised against an immunogen of the following structure:
wherein the accm is an antigenicity conferring carrier material;
wherein the crosslinker is a functionalised linking group joining the accm to the remainder of the molecule, the crosslinker forming a double bond to the cyclohexyl ring;
wherein m is 3;
wherein the antibody has a cross-reactivity presented as B/B0 of ≦50% against (±) CP-47,497 (C7 homologue) at a concentration of 100 ng/ml and a cross-reactivity presented as B/B0 of ≦50% against (±)-CP-47,497 (C8 homologue) at a concentration of 100 ng/ml, and
wherein the antibody has a cross-reactivity presented as B/B0 of greater than 80% against each one of the cross-reactants selected from the group consisting of (±)-CP-47,497 (C7 para quinone analogue), (±)-CP-55,940, (−)-CP 55,940, (+)-CP 55, 940, HU-210, HU-211 (dexanabinol), HU-308, delta9-THC, and (−)-11-nor-9-carboxy-delta9-THC, at a cross-reactant concentration of 100 ng/ml,
wherein the B/B0 is measured using (±)-CP-47,497 (C8 homologue) as a standard and Tracer 1 as a tracer, of the following structural formula:
wherein B0 is absorbance at 450 nm at zero ng/ml standard concentration, and
wherein B is absorbance at 450 nm at predetermined variable standard concentrations.